{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '5.2', 'SECONDARY', '36', '6', 'STUDY DESIGN', '37', '6.1', 'DESCRIPTION OF THE STUDY', '37', '6.2', 'DURATION OF STUDY PARTICIPATION', '37', '6.2.1', 'Duration of study participation for each patient', '37', '6.2.2', 'Determination of end of clinical trial (all patients)', '37', '6.3', 'INTERIM ANALYSIS', '37', '6.4', 'STUDY COMMITTEES', '38', '6.4.1', 'Data Monitoring Committee', '38', '7', 'SELECTION OF PATIENTS', '39', '7.1', 'INCLUSION CRITERIA', '39', '7.2', 'EXCLUSION CRITERIA', '40', '7.2.1', 'Exclusion criteria related to study methodology', '40', '7.2.2', 'Additional exclusion criteria during or at the end of screening before randomization', '42', '8', 'STUDY TREATMENTS', '43', '8.1', 'INVESTIGATIONAL MEDICINAL PRODUCT(S) / NON INVESTIGATIONAL MEDICINAL', 'PRODUCT(S)', '43', '8.1.1', 'INVESTIGATIONAL MEDICINAL PRODUCT(S)', '43', '8.1.2', 'NON INVESTIGATIONAL MEDICINAL PRODUCT(S', '44', '8.1.2.1', '13N-ammonia and 82Rubidium', '44', '8.1.2.2', 'Adenosine and regadenoson', '44', '8.2', 'BLINDING PROCEDURES', '44', '8.2.1', 'Methods of blinding', '44', '8.2.2', 'Randomization code breaking during the study', '44', '8.3', 'METHOD OF ASSIGNING PATIENTS TO TREATMENT GROUP', '45', '8.4', 'PACKAGING AND LABELING', '45', '8.5', 'STORAGE CONDITIONS AND SHELF LIFE', '46', '8.6', 'RESPONSIBILITIES', '46', '8.6.1', 'Treatment accountability and compliance', '46', '8.6.2', 'Return and/or destruction of treatments', '47', '8.7', 'CONCOMITANT MEDICATION', '47', '9', 'ASSESSMENT OF INVESTIGATIONAL MEDICINAL PRODUCT', '49', 'Property of the Sanofi Group - strictly confidential', 'Page 23', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '9.1', 'EFFICACY ENDPOINTS', '49', '9.1.1', 'Primary efficacy endpoint', '49', '9.1.2', 'Secondary efficacy endpoint', '49', '9.1.3', 'Exploratory endpoints', '49', '9.1.4', 'Assessment methods and activity parameters', '49', '9.1.4.1', '13N-ammonia or B\u00b2Rubidium PET scan', '49', '9.1.4.2', 'Analysis of rest and stress myocardial perfusion PET images', '50', '9.1.4.3', 'Angina episodes and short-acting nitrates:', '51', '9.1.4.4', 'Patient Reported Outcomes', '51', '9.1.4.5', 'Coronary computed tomography angiography', '53', '9.2', 'SAFETY ENDPOINTS', '53', '9.2.1', 'Adverse events', '53', '9.2.2', 'Physical examination', '53', '9.2.3', 'Laboratory safety variables', '54', '9.2.4', 'Vital signs', '54', '9.2.4.1', 'Technical aspects', '54', '9.2.4.2', 'Screening visit (determination of reference arm)', '55', '9.2.4.3', 'Measurements for assessing presence or not of orthostatic hypotension', '55', '9.2.5', 'Electrocardiogram variables', '55', '9.3', 'PHARMACOKINETIC ENDPOINT', '56', '9.3.1', 'Pharmacokinetics', '56', '9.3.1.1', 'Sampling time', '56', '9.3.1.2', 'Pharmacokinetics handling procedure', '56', '9.3.1.3', 'Bioanalytical method', '56', '9.3.1.4', 'Pharmacokinetics parameters', '57', '9.3.2', 'Pharmacogenetic assessment', '57', '9.3.2.1', 'Drug metabolizing enzymes DNA sample', '57', '9.3.2.2', 'Optional stored DNA sample', '57', '9.4', 'BIOMARKER ENDPOINTS', '57', '9.4.1', 'Sampling / handling procedures', '58', '9.4.2', 'Biomarker assay methods', '58', '9.5', 'FUTURE USE OF SAMPLES FOR BIOMARKER SAMPLES', '58', '9.6', 'SAMPLE BLOOD VOLUME', '59', '9.7', 'APPROPRIATENESS OF MEASUREMENTS', '59', '10', 'STUDY PROCEDURES', '61', '10.1', 'VISIT SCHEDULE', '61', '10.1.1', 'Visit 0: Screening visit', '61', 'Property of the Sanofi Group - strictly confidential', 'Page 24', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}